1 Skeletal effects of sleeve gastrectomy, by sex and menopausal status and in comparison 2 to Roux-en-Y gastric bypass surgery 3 4 Karin C Wu^{1,2}, Po-Hung Wu³, Galateia Kazakia³, Sheena Patel⁴, Dennis M Black⁵, Thomas F 5 Lang³, Tiffany Y Kim^{1,2}, Nicole J King², Thomas J. Hoffman^{5,6}, Hanling Chang², Gaia Linfield¹, Sarah Palilla⁷, Stanley J Rogers⁷, Jonathan T Carter⁷, Andrew M Posselt⁷, Anne L Schafer^{1,2,5} 6 7 8 1. Department of Medicine, University of California San Francisco, San Francisco, CA, USA. 9 2. Endocrine Research Unit, San Francisco Veterans Affairs Health Care System, San 10 Francisco, CA, USA. 3. Department of Radiology, University of California San Francisco, San Francisco, CA, USA. 11 4. California Pacific Medical Center Research Institute, San Francisco, CA, USA. 12 13 5. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. 14 6. Institute for Human Genetics, University of California San Francisco, San Francisco, CA, 15 USA. 16 17 7. Department of Surgery, University of California San Francisco, San Francisco, CA, USA. 18 19 **Corresponding Author & Reprint Requests:** 20 Karin C. Wu, MD 700 Owens St. RM 349, San Francisco, CA 94158 | Email: karin.wu@ucsf.edu 21 22 23 Competing Interests: All authors have completed the ICMJE uniform disclosure form 24 25 at www.icmje.org/coi_disclosure.pdf and declare: Calcium citrate supplements were donated by 26 Bariatric Advantage for the submitted work; ALS has received investigator-initiated research

- 27 funding from Amgen and grant support from Bone Health Technologies; no other relationships
- 28 or activities that could appear to have influenced the submitted work.
- 29
- **Funding**: This study was funded by the National Institute of Diabetes and Digestive and Kidney
- 31 Diseases (NIDDK, R01DK107629). Additional support came from a VA Career Development
- 32 Award (1IK2CX000549) to ALS, the NIDDK grant P30DK098722, the National Institute of
- 33 Arthritis and Musculoskeletal and Skin Diseases (NIAMS, P30AR075055), the National Center
- for Advancing Translational Sciences (UL1TR001872), and the Northern California Institute for
- 35 Research and Education. KCW has received support from the Department of Veterans Affairs
- 36 and the NIDDK (T32DK007418). TYK is supported by a VA Career Development Award
- 37 (11K2CX001984). Calcium citrate supplements were donated by Bariatric Advantage.
- 38 Manuscript content is solely the responsibility of the authors and does not necessarily represent
- 39 the official views of the National Institutes of Health.
- 40

41 Data Availability:

42 All data produced in the present study are available upon reasonable request to the authors.

44 Abstract

- 45 <u>Context</u>: Roux-en-Y gastric bypass (RYGB) has deleterious effects on bone mass,
- 46 microarchitecture, and strength. Data are lacking on the skeletal effects of sleeve gastrectomy
- 47 (SG), now the most commonly performed bariatric surgical procedure.
- 48 *<u>Objective</u>*: We examined changes in bone turnover, areal and volumetric bone mineral density
- 49 (aBMD, vBMD), and appendicular bone microarchitecture and estimated strength after SG. We
- 50 compared the results to those previously reported after RYGB, hypothesizing lesser effects after
- 51 SG than RYGB.
- 52 <u>Design, Setting, Participants</u>: Prospective observational cohort study of 54 adults with obesity
- 53 undergoing SG at an academic center.
- 54 Main Outcome Measure(s): Skeletal characterization with biochemical markers of bone
- 55 turnover, dual-energy X-ray absorptiometry (DXA), quantitative computed tomography (QCT),
- 56 and high-resolution peripheral QCT (HR-pQCT) was performed preoperatively and 6- and 12-

57 months postoperatively.

- 58 <u>*Results*</u>: Over 12 months, mean percentage weight loss was 28.8%. Bone turnover marker
- 59 levels increased, and total hip aBMD decreased -8.0% (95% CI -9.1%, -6.7%, p<0.01). Spinal
- aBMD and vBMD declines were larger in postmenopausal women than men. Tibial and radial
- 61 trabecular and cortical microstructure worsened, as did tibial estimated strength, particularly in
- 62 postmenopausal women. When compared to data from a RYGB cohort with identical design and
- 63 measurements, some SG biochemical, vBMD, and radial microstructural parameters were
- 64 smaller, while other changes were not.
- 65 <u>*Conclusions*</u>: Bone mass, microstructure, and strength decrease after SG. Some skeletal 66 parameters change less after SG than after RYGB, while for others, we find no evidence for
- 67 smaller effects after SG. Postmenopausal women may be at highest risk of skeletal
- 68 consequences after SG.

70 Introduction

71 One in 11 US adults (9.2%), and one in nine US women (11.2%), are living with severe or Class 72 3 obesity (body mass index [BMI] \geq 40 kg/m²) (1). Obesity is linked to multiple comorbid 73 conditions and is associated with increased mortality (2, 3). Metabolic and bariatric surgery 74 (MBS) is a highly effective intervention for severe obesity, leading to marked and durable weight 75 loss, improvement in obesity-associated diseases, and decreased mortality (4, 5). However, 76 Roux-en-Y gastric bypass (RYGB), previously the most popular procedure and often considered 77 the gold-standard for metabolic benefit, has been shown to induce detrimental effects on 78 calcium homeostasis and skeletal health, with increases in bone turnover, decreases in bone mineral density (BMD), weakened bone microarchitecture, and increased fracture incidence (6-79 80 15). 81 82 Sleeve gastrectomy (SG) has emerged over the last decade and has overtaken RYGB as the most commonly performed weight loss operation in the US and around the world (16, 17). SG 83 involves the removal of 60-80% of the stomach mass along the greater curvature, without the 84 alteration of the intestinal pathway that characterizes RYGB. Its rise in patient and surgeon 85 86 preference is largely due to the simpler surgical approach, lower peri- and postoperative 87 complication and mortality rates, and roughly clinically comparable long-term weight loss and metabolic benefits (5, 18, 19). However, the impact of SG on skeletal health is still not well 88 characterized. 89

90

Published studies of skeletal effects of SG have generally examined areal BMD (aBMD) by
dual-energy X-ray absorptiometry (DXA), but DXA may be biased in the setting of marked body
composition changes and degenerative changes in the spine. Quantitative computed
tomography (QCT) and high-resolution peripheral QCT (HR-pQCT) are three-dimensional, non-

95 invasive methods for assessing volumetric BMD (vBMD) at the axial and appendicular skeleton 96 and for examining cortical and trabecular bone microarchitecture and estimated bone strength 97 (20, 21). Further, studies have inconsistently addressed the vitamin D deficiency that is so 98 common in severe obesity and with dietary restriction. Moreover, the relative skeletal effects of 99 SG by sex and menopausal status are uncertain. Because the majority of individuals who 100 undergo bariatric surgery are premenopausal women, studies of postoperative skeletal changes 101 after SG have largely focused on that group (22-25). However, postmenopausal women's 102 skeletons, already vulnerable due to age and sex steroid deficiency, may be particularly 103 affected, as we have shown after RYGB (13). If this is the case after SG, there may be clinical implications for targeted screening and postoperative management. 104 105 106 The aim of this study was to examine the effects of SG on aBMD, vBMD, and appendicular 107 microarchitecture and estimated strength in a cohort of pre- and postmenopausal women and 108 men with severe obesity, in the setting of optimized 25-hydroxyvitamin D (25OHD) status and

recommended calcium intake. We also aimed to compare observed skeletal changes after SG
with changes reported in our previous cohort study of RYGB (13), which employed an identical
protocol and measurements. We hypothesized that bone mass, microstructure, and estimated

strength would decline, but to a lesser extent than RYGB, after SG.

113

114 Materials and Methods

115

116 <u>Study design & population</u>

117 We recruited women and men with severe obesity, aged 25 to 70 years, from an academic

bariatric surgery center (the University of California, San Francisco [UCSF]), as previously

described (26). Participants were eligible if they were scheduled for an upcoming SG procedure,

120 which was done laparoscopically and sometimes with robotic assist. Eligibility for bariatric

121	surgery at our institution was in accordance with the 1991 National Institutes of Health
122	consensus conference (BMI \ge 40 kg/m ² or \ge 35 kg/m ² with obesity-related comorbid conditions)
123	(27) and failure to lose weight with medical management. For this cohort study, we excluded
124	perimenopausal women (last menses > 3 months but < 4 years ago), and additional exclusion
125	criteria included a history of intestinal malabsorption or prior bariatric surgery, use of
126	medications known to impact bone and mineral metabolism (e.g. osteoporosis
127	pharmacotherapy, glucocorticoids, thiazolidinediones, aromatase inhibitors, androgen
128	deprivation therapy), diseases known to affect bone (e.g. primary hyperparathyroidism, Paget's
129	disease, hyperthyroidism defined by TSH < 0.1 mIU/L, clinically significant liver disease), illicit
130	drug use or alcohol use > 3 drinks/day, hypercalcemia (serum calcium > 10.2 mg/dL), chronic
131	kidney disease stage 4 or lower (eGFR < 30 mL/min/1.73 m^2), and weight > 200 kg (weight limit
132	of the DXA scanner).
133	
134	Participants underwent study measurements preoperatively (no more than 3 months before the
135	SG) and at 6 months and 12 months postoperatively. However, the COVID19 pandemic
136	impeded our ability to adhere to the predefined timeline, particularly for the 12-month
137	postoperative visit. The mean \pm standard deviation (SD) for the 6-month postoperative timepoint
138	was 7.5 \pm 1.6 months and for the 12-month postoperative timepoint was 17.6 \pm 9.7 months.
139	After examining the distribution, we excluded data collected after 20 months postoperatively.
140	
141	Protocol approval was obtained from the Institutional Review Board at the University of
142	California, San Francisco. Written informed consent was obtained from all participants. The
143	study was registered at the US National Institutes of Health (ClinicalTrials.gov, NCT02778490).

144

For comparison between SG and RYGB procedures, we used a previously completed (5 years
prior) pre-post observational cohort study of 48 women and men ages 25 to 70 years with

147	severe obesity undergoing RYGB at UCSF and the San Francisco Veterans Affairs Health Care
148	System (13, 28). The two cohort studies employed the identical approach/protocol, and
149	measurements and were made by the same research team, sequentially. The SG study was
150	designed to accommodate careful comparisons between these two cohorts.
151	
152	Calcium and vitamin D supplementation
153	The research protocol included standardization of calcium intake and attention to vitamin D
154	status, following emerging clinical practice guidelines (29, 30). Vitamin D and chewable calcium
155	citrate supplements were provided upon enrollment (at least 2 weeks prior to the preoperative
156	measurements) and supplied throughout the study period. At enrollment, low 25OHD levels
157	were repleted to a target level ≥ 30 ng/mL, and vitamin D was supplemented with at least 3000
158	IU/day. Each participant's total daily calcium intake was brought to 1200 mg through
159	individualized calcium citrate dosing, based on estimation of intake from a validated screener
160	(31). Postoperatively, 25OHD levels and estimated dietary calcium intake were monitored, and
161	each participant's supplement doses were adjusted to maintain the vitamin D and calcium intake
162	goals.
163	
164	Study measures
165	DXA bone density and body composition
166	Areal BMD (aBMD, g/cm ²) at the lumbar spine (L1 to L4), proximal femur, and distal radius was
167	measured using DXA (Horizon A, Hologic) at each study time point. Whole-body DXA were also
168	performed for assessment of estimated total and regional body composition, including
169	percentage body fat (32). If the body dimensions exceeded the width of the scanning area, the
170	DXA manufacturer's reflection technique was utilized.
171	

172 QCT for spine bone density

Spinal volumetric BMD (vBMD, g/cm³) was assessed by QCT at the L3 and L4 vertebrae at 120
kVp, 200 mAs (General Electric's VCT64 scanner; General Electric, Milwaukee, WI, USA) at
each study time point and was analyzed according to methods previously described (Mindways
Software, Austin, TX, USA) (33, 34).

177

178 HRpQCT for appendicular bone density, microarchitecture, and estimated strength

179 Participants were imaged with a HRpQCT system (XtemeCT1, Scanco Medical, Brüttisellen,

180 Switzerland) at each study time point, using the manufacturer's standard in vivo protocol

181 (source potential 60 kVp, tube current 900 µA, isotropic 82 µm nominal resolution) (35-37). The

182 nondominant forearm and ankle were scanned. Fixed scan regions started at 9.5 mm proximal

to the mid-joint line for the ultradistal radius and 22.5 mm for the ultradistal tibia and extended

proximally for 9.02 mm (110 slices). Images were individually examined and rated for artifacts

as a result of soft tissue extension outside the field of view.

186

187 HR-pQCT images were analyzed using the manufacturer's standard clinical evaluation protocol 188 in Image Processing Language (IPL v5.08b, Scanco Medical) (38-40). Contours identifying the 189 periosteal perimeter of the bone were drawn semi-automatically using an edge-finding algorithm 190 (40) and manually examined and modified as necessary. A threshold-based process was used 191 to segment cortical and trabecular regions (40) and was manually checked for accurate 192 segmentation. Trabecular structure and cortical parameters were assessed using methods 193 previously described (41). Linear elastic micro-finite element analysis (µFEA, Scanco FE 194 Software, Scanco Medical) was used to calculate biochemical properties (41-43).

195

196 Other measures

197 Weight and height were measured at each study time point, and BMI (kg/m²) was calculated. Waist circumference was measured at the level directly below the lowest rib, and hip 198 199 circumference at the maximum extension of the buttocks, viewed from the side. 200 201 Participants collected 24-hour urine specimens at each time point for measurement of urinary 202 calcium and creatinine. Serum samples were collected after an overnight fast at each study time 203 point. Basic chemistries including calcium, albumin, and phosphate, 25OHD, and parathyroid 204 hormone (PTH) were measured at a commercial laboratory (Quest Diagnostics, Secaucus, NJ, 205 USA). Additional serum samples were stored at -80°C until batch analyzed in a central 206 laboratory (MaineHealth Institute for Research, Scarborough, ME, USA). Serum C-terminal 207 cross-linked telopeptide (CTx; a marker of bone resorption), procollagen type 1 N-terminal 208 propeptide (P1NP; a marker of bone formation), and 1,25-dihydroxyvitamin D (1,25[OH]₂D) were 209 measured by chemiluminescence on an auto-analyzer (iSYS, Immunodiagnostic Systems, 210 Scottsdale, AZ). The inter- and intra-assay coefficients of variation (CV) were 6.0% and 3.2% for 211 CTx, 5.0% and 2.9% for P1NP, and 11.1% and 6.4% for 1,25(OH)₂D. Intestinal fractional 212 calcium absorption (FCA) was measured preoperatively and at 6 months postoperatively by a 213 gold-standard dual stable calcium isotope tracer method, as previously reported (26). 214

215 <u>Statistical methods</u>

Sample size calculations for this study were based on the mean changes, SD, and covariance parameters identified in our previous pre-post RYGB cohort study (13), which had comparable study population, study protocol, and measurements. We calculated that a sample of 50 participants would provide 80% power in 2-sided tests with α = 0.05 to detect a percentage reduction in femoral neck, total hip, and lumbar spine aBMD of 2.0%, 2.1%, and 1.8%, respectively. These approximate the least significant change for DXA at our institution and the change commonly considered clinically significant.

223

224 Baseline descriptive data were reported as means ± SD, median (interguartile range [IQR]), or 225 proportions (N [%]). One-way ANOVA or Kruskal-Wallis were used as appropriate to determine 226 differences in baseline characteristics between sex and menopausal status (premenopausal 227 women, postmenopausal women, and men). Changes in weight and bone parameters over time 228 after SG were analyzed using mixed effect models with repeated measures with random subject 229 intercept and slope and fixed effect of time, with and without the interactions of sex and 230 menopausal status. Models were fitted with maximum likelihood estimation and were tested for 231 non-linear relationships with a quadratic time term. The percentage change in bone parameters over 6 and 12 months and the confidence intervals for the predicted percentage changes were 232 estimated with model-based parametric bootstrap with 1000 resamples. Participants were 233 234 excluded from analysis if the 6-month postoperative percentage change for that bone parameter 235 was > 3SD above or below the mean, suggesting a problem with the measurement of that 236 parameter.

237

238 Comparisons of the changes in bone imaging parameters, body composition, and laboratory 239 parameters between RYGB and SG were analyzed similarly using mixed effect models with 240 repeated measures with random subject intercept and slope and fixed effect of time*procedure. 241 These models were adjusted for age, sex, menopausal status, race, baseline weight, and 242 diabetes status, which were determined a priori in light of the relevant biology. Paired t-test or 243 Wilcoxon signed-rank tests were performed as appropriate to determine whether the changes in 244 bone turnover markers and FCA between preoperative and 6-month postoperative timepoints 245 differed between RYGB and SG cohorts. Linear models were then used to estimate the 246 adjusted associations. The 6-month postoperative data was used for comparison because it is 247 the study visit that is more closely matched in time since surgery between the two cohorts, given 248 the impact of the COVID19 pandemic on follow-up after SG. Further, the use of one

- 249 postoperative timepoint minimize the batch effect of serum analyses, and FCA was measured
- 250 only at the 6-month postoperative timepoint.
- 251
- 252 Statistical significance level was set at a two-sided p-value < 0.05, with corresponding 95%
- 253 confidence intervals. All data sets were managed using SAS software (version 9.4, SAS
- Institute Inc., Cary, North Carolina, USA) and all statistical analyses were done using R (version
- 255 4.0.3) (44).
- 256
- 257 Results
- 258

259 Baseline SG participant characteristics

260 Fifty-four participants completed both pre- and postoperative skeletal imaging assessments.

Preoperatively, mean age \pm SD was 46.2 \pm 11.1 years, weight was 126.0 \pm 23.4 kg, and BMI

was 45.2 ± 7.5 kg/m² (Table 1). Of the 54 participants, 41 (76%) were women, with 15 (37%) of

those postmenopausal and 26 (63%) premenopausal. Mean 25OHD level at the preoperative

skeletal imaging assessments was 40.6 ± 13.7 ng/mL, which reflected preoperative repletion of

low levels that had been performed in accordance with clinical practice guidelines (29, 30).

266 Mean serum calcium, PTH, 1,25(OH)₂D, serum creatinine, and serum phosphorate were within

- their reference ranges. Median 24-hour urinary calcium level was 172 mg (IQR 80 to 270 mg).
- 268

269 Mean age for men was higher than for premenopausal women, but lower than for

postmenopausal women. Preoperative BMI was similar across sex and menopause groups.

However, men had higher preoperative weight, lower percentage body fat, higher waist

272 circumference, and higher waist-to-hip ratio. Vitamin D status, PTH, and other measures of

- 273 calcium homeostasis (FCA and 24-hour urinary calcium) did not differ by sex and menopausal
- status. Men had higher bone turnover marker levels compared to premenopausal women.

275 Baseline aBMD by DXA at the spine and proximal femur did not differ by sex and menopause

status. Postmenopausal women and men had lower preoperative lumbar spine vBMD than

- 277 premenopausal women.
- 278
- 279 Weight loss after SG
- 280 Weight loss was dramatic after SG, with predicted 6-month percentage weight loss -21.8%

281 (95% CI -23.8%, -19.9%) of preoperative weight, and 12-month percentage weight loss -28.8%

282 (-31.3%, -26.0%) (p < 0.01 for both). Percentage weight loss did not differ by sex or

- 283 menopausal status.
- 284

285 Changes in biochemical markers of bone turnover after SG

Bone turnover markers increased markedly after SG. Serum CTX, a marker of bone resorption,

increased by a median +156% (IQR +89% to +279%) over 6 months, then at 12 months it was

still +87% above baseline (IQR +38% to +175%) (p < 0.01 for both). Serum P1NP, a marker of

bone formation, increased by a median +58% (IQR +33% to +100%) over 6 months, then at 12

months it was still +47% above baseline (IQR +11% to +82%) (p < 0.01 for both).

291

292 Changes in BMD after SG

Areal BMD at the proximal femur (DXA) decreased progressively after SG (Table 2), with

predicted 6- and 12-month declines at the femoral neck of -3.4% and -6.7%, respectively, and at

the total hip of -5.4% and -8.0%, respectively (p<0.01 for both). There was a decline in lumbar

spine aBMD (p = 0.03) and a trend for decline in lumbar spine vBMD (p = 0.07). The decline in

297 lumbar spine aBMD by DXA was larger for postmenopausal women than for premenopausal

women or men (Figure 1a). The decline in lumbar spine vBMD by QCT was larger for women

- than for men, with a decline of -5.8% in premenopausal women and -3.6% in postmenopausal
- 300 women vs. an increase of +8.2% in men over 12 months (Figure 1b).

2	Δ	1
J	υ	

302	Declines in appendicular vBMD after SG, measured by HR-pQCT, were smaller in magnitude
303	than declines in axial BMD. The decline in trabecular vBMD at the radius and tibia and total
304	vBMD at the tibia were statistically significant. The declines in total vBMD and cortical vBMD at
305	the tibia were largest in postmenopausal women (tibia total vBMD over 12 months: -5.8% in
306	postmenopausal women vs2.4% in premenopausal women vs1.1% in men, Figure 1c; tibia
307	cortical vBMD over 12 months: -3.3% in postmenopausal women vs0.5% in premenopausal
308	women vs. +0.4% in men, Figure 1d).
309	
310	Changes in bone microarchitecture and estimated strength after SG
311	Within the trabecular compartment, changes in microarchitecture associated with diminished
312	skeletal strength were observed at the tibia and the radius (Table 3). There were decreases in
313	trabecular number and increases in trabecular separation and trabecular heterogeneity, as well
314	as in trabecular thickness. Increases in trabecular separation at the radius and trabecular area
315	at the tibia were larger for postmenopausal women (Figures 1e, 1f). Within the cortical
316	compartment, cortical pore size increased at both the radius and tibia (Table 3). There was also
317	a decrease in cortical thickness at the tibia, which was larger for postmenopausal women than
318	premenopausal women (Figure 1g).
319	

Postoperative changes in estimated bone strength were apparent at the tibia, although not at the radius (Table 3). Declines in failure load, stiffness, and apparent modulus were all worse in postmenopausal women (Figure 1h, 1i, and 1j). The predicted decline in failure load over 12 months was -5.7% in postmenopausal women vs. -1.7% in premenopausal women vs. +0.3 in men; the predicted decline in stiffness over 12 months was -5.5% in postmenopausal women vs. -0.9% in premenopausal women vs. +1.3% in men; and the predicated decline in apparent

modulus over 12 months was -5.2% in postmenopausal women vs. -0.9% in premenopausal
women vs. +1.3% in men.

328

329 Comparison of participant characteristics and metabolic outcomes in the SG and RYGB cohort 330 studies 331 We used data from our previous pre-post observational cohort study of adults undergoing 332 RYGB (13), which employed an identical study design and measurements, to make careful 333 comparisons of the skeletal effects of SG and RYGB. At preoperative baseline, characteristics 334 were similar between cohorts. There were no differences in age, sex and menopausal distribution, race, baseline weight and BMI, calciotropic hormone levels, or FCA. There were 335 more participants with diabetes in the RYGB cohort than in the SG cohort (40% vs. 19%, p =336 337 0.03). 338 339 Postoperatively, percentage weight loss after SG approached, but was smaller than that after 340 RYGB (-21.9% after SG vs. -25.1% after RYGB over 6 months; -28.8% after SG vs. -30.8% 341 after RYGB over 12 months; p < 0.01 for procedure*time interaction in adjusted models). 342 Decrease in intestinal fractional calcium absorption over 6 months, reported previously not only

for RYGB (28) but also after SG (26), was worse after RYGB vs. SG (absolute mean decline of -

25.8% vs. -17.9%, p < 0.01 procedure*time interaction in adjusted models).

345

346 Changes in skeletal parameters in comparison with RYGB

347 Increases in bone turnover marker levels were larger after RYGB than after SG. The bone

resorption marker CTx increased by a median +276% (IQR +166% to +395%) over the 6

months after RYGB vs. by +156% (IQR +89% to +279%) after SG (p <0.01 for difference

between procedures). The bone formation marker P1NP 6 months postoperatively increased by

a median +112% (IQR +71% to +153%) after RYGB vs. by +58% (IQR +33% to +100%) after

SG (p <0.01 for difference between procedures). Differences between procedures persisted
 even with adjustment for age, sex, menopausal status, and race.

354

355 By DXA, there was no evidence for differences between SG and RYGB in the extent of aBMD 356 decline at the proximal femur or lumbar spine. However, decline in lumbar spine vBMD by QCT 357 was larger after RYGB than SG (-7.8% after RYGB vs. -3.2% after SG over 12 months; Figure 358 2a). There was also a larger decline after RYGB than SG in total vBMD at the radius (Figure 359 2b). In terms of bone microarchitecture, at the radius, cortical thickness decreased more and 360 trabecular area increased more after RYGB (Figures 2c and 2d). In contrast, there were larger changes after SG than RYGB in the trabecular compartment at the tibia, including larger 361 decreases in trabecular number and larger increases in trabecular separation and trabecular 362 363 heterogeneity (Figures 2e, 2f, 2g). There was no evidence for differences between surgical 364 procedures in estimated strength parameter change. All models were adjusted for age, sex, 365 menopausal status, race, preoperative weight, and diabetes status. To test whether the larger 366 weight loss after RYGB explained the larger change after RYGB for spinal vBMD or the larger changes after RYGB at the radius for total vBMD, cortical thickness, or trabecular area, we 367 368 entered weight change into the multivariable model. For spinal vBMD change, adjustment for 369 weight change diminished the difference between surgical procedures, in that the point estimate 370 decreased by 31% and the p-value for procedure*time was no longer statistically significant. In 371 contrast, for radius total vBMD, cortical thickness, and trabecular area, point estimates changed 372 minimally and the differences between RYGB and SG maintained statistical significance.

373

374 Discussion

375

This prospective cohort study of SG and skeletal health is the largest to date to examine axial and appendicular vBMD and appendicular bone microarchitecture and estimated strength. We

found detrimental effects of SG on bone mass, structure, and strength that worsened
progressively throughout the study duration (up to 20 months postoperatively). Our study is
unique in its examination of the relative skeletal effects of SG by sex and menopausal status.
Postmenopausal women are the population most burdened by lower bone mass and worse
bone microstructure, and in our data this group experienced the largest declines in many
skeletal health parameters after SG, including changes in BMD, bone microstructure, and
estimated strength.

385

386 At the axial skeleton, postoperative declines in BMD occurred early and were substantial, particular at the proximal femur. The predicted 12-month percentage changes in aBMD were 387 comparable to the magnitude of bone loss expected over the 3-4 years of fastest bone loss 388 389 during the menopausal transition (45). Although the changes in lumbar spine vBMD by QCT 390 overall did not reach statistical significance, a decline was observed in women that was offset by 391 an increase in men. It is unclear why men had an increase in spine vBMD. One speculation is 392 that men tend to have more degenerative disc disease, which may be a cause of spurious 393 elevation not only for spine aBMD by DXA but also spine vBMD by QCT (46). In addition, in the 394 setting of higher preoperative weight and waist circumference in men, greater preoperative 395 abdominal soft tissue extension outside the CT scanner field of view could have result in more 396 beam hardening artifact (47). Beam hardening could result in underestimation of vBMD at 397 baseline and then an apparent increase in vBMD as weight is lost. Although QCT avoids the 398 biases of DXA that stem from 2-dimensional, single-projection data acquisition, QCT 399 assessments have nevertheless been shown to be influenced by obesity and weight loss (48). 400

There were also statistically significant declines in appendicular vBMD, albeit smaller in
 magnitude than at the axial sites. At the radius and tibia, both the trabecular and cortical
 compartments sustained detrimental effects, including decreases in trabecular number and

404 increases in trabecular separation and heterogeneity and cortical pore size. The fact that these 405 changes occurred at both the weight-bearing tibia and non-weight-bearing radius suggests at 406 least in part a systematic nature of the skeletal effects of SG. However, the deterioration in bone 407 density and microarchitecture was more pronounced at the weight-bearing skeleton. At the tibia, 408 there were additional increases in trabecular area with decreases in cortical thickness at the 409 tibia, consistent with endocortical resorption, and the impairment in bone density and 410 microarchitecture translated into declines in estimated strength. The specificity for the tibia 411 suggests that the mechanical unloading of weight loss may contribute in part to overall skeletal 412 changes.

413

414 Postmenopausal women had worse declines than premenopausal women and men in some 415 bone mass and microarchitectural parameters and in all estimated strength parameters at the 416 tibia. This may reflect a heightened sensitivity of the already vulnerable postmenopausal 417 skeleton—already vulnerable from age and sex hormone deficiency—to SG-induced bone 418 metabolism abnormalities. The findings corroborate our previously reported finding that 419 postmenopausal women were particularly impacted by skeletal effects of RYGB (13). If 420 postmenopausal women are at highest risk for bariatric surgery-induced skeletal complications, 421 there are implications for clinical care; it may be appropriate to target postmenopausal women 422 with skeletal health screening, monitoring, and therapeutic interventions as they undergo RYGB 423 or SG. Interventions have been studied: For example, a randomized controlled trial of a 424 multipronged program of exercise, calcium, vitamin D, and protein supplementation was able to 425 attenuate postoperative bone loss compared to no intervention in premenopausal women and 426 men undergoing RYGB or SG (49). Ongoing clinical trials are now examining the safety and 427 efficacy of osteoporosis pharmacologic interventions to reduce bariatric surgery-associated 428 bone loss.

429

430 We were uniquely positioned to compare the skeletal effects of SG to those of RYGB, as we 431 previously conducted a pre-post RYGB cohort study with identical study design and protocol 432 (13). The two cohorts were remarkably similar in baseline characteristics, but we nevertheless 433 adjusted our models for key baseline parameters. Increases in bone turnover marker levels 434 were larger after RYGB than after SG. For DXA-assessed aBMD change, we did not detect 435 differences between the surgical procedures. This finding is consistent with a recent meta-436 analysis of 14 studies on the effects of RYGB vs. SG on bone mineral density, which did not 437 identify significant differences in aBMD change at the total hip, femoral neck, and lumbar spine 438 (50). No prior studies have examined QCT or HRpQCT BMD, bone microstructure, or estimated strength between procedures. By QCT, we found that spinal vBMD decline was worse after 439 440 RYGB than after SG. By HRpQCT, at the radius we demonstrated worse total vBMD decline 441 and worse cortical thickness decline (with associated increase in trabecular area) after RYGB 442 than after SG. Conversely, at the tibia, SG seemed to lead to worse microarchitectural changes 443 in the trabecular compartment than RYGB. There were no differences in the decline in 444 estimated bone strength between the two surgical procedures.

445

446 A number of potential factors may explain differential skeletal outcomes after the two surgical 447 procedures. One such factor is extent of weight loss, which was not quite as large after SG as 448 after RYGB. Our analyses suggest that the larger decline in spinal vBMD after RYGB compared 449 to SG was explained by the greater weight loss experienced by the RYGB cohort. However, the 450 larger declines at the radius for total vBMD and cortical thickness (with associated increase in 451 trabecular area) after RYGB were not explained by greater weight loss after RYGB. Participants 452 in both our cohorts underwent measurement of intestinal fractional calcium absorption, reported 453 previously (26, 28), using a gold-standard dual stable isotope method. Decline in intestinal 454 calcium absorption after SG, while marked, was less severe than after RYGB. This could 455 contribute to the larger bone turnover marker increases and larger changes in select parameters

456 at the radius after RYGB compared to SG. There are fewer potential explanations for our finding 457 that SG seemed to lead to worse trabecular microarchitectural changes than RYGB at the tibia. 458 In a published study comparing RYGB and SG over 12 months, there was an increase in bone 459 marrow adiposity after SG but not RYGB (51), and one could speculate that an increase in 460 marrow adiposity could lead to worsening trabecular microarchitecture. 461 462 Major strengths of our study include its prospective, longitudinal design, and the very 463 comprehensive measurement of skeletal health using DXA, QCT, and HRpQCT as well as 464 biochemical markers of bone turnover. Our cohort is unique as it included nearly 30% of postmenopausal women and nearly 25% of men, who are often excluded from or play a small 465 role in SG research, because the majority of patients undergoing bariatric surgery are 466 467 premenopausal women. Indeed, in a prior worldwide study from 2018, 73.7% of patients 468 undergoing bariatric surgery were women with a median (IQR) age of 42 years (33-51) (17). Our 469 study protocol included the careful, individualized supplementation of calcium and vitamin D in 470 order to study the skeletal effects of SG in the setting of adherence to current standardized 471 professional recommendations (52).

472

A limitation of our study is its modest duration; we did not determine the longer-term skeletal 473 474 effects in our cohorts. The COVID19 pandemic impeded our ability to adhere to the protocol's 475 predefined timeline for study visits. However, we completed follow-up when we were able to do 476 so, in fact exceeding our planned sample size, and we revised our statistical analysis plan to 477 employ robust mixed-effect models taking into account the time to follow-up. Although we were 478 able to make comparisons between SG and RYGB procedures using data from pre-post cohort 479 studies that employed the same protocol and measurements and drew from the same bariatric 480 surgery center, this was not a randomized controlled trial, nor was there a nonsurgical control 481 group for full comparison. While our study is the largest to date to examine axial and

appendicular vBMD and appendicular bone microarchitecture and strength, the sizes of the sex
and menopause subgroups were modest. Future studies should enroll larger groups of
postmenopausal women and men.

485

486 In conclusion, SG negatively impacts axial and appendicular BMD and appendicular bone 487 microarchitecture and estimated strength. Increases in bone turnover marker levels and 488 declines in some measures of bone mass and microarchitecture, while clinically and statistically 489 significant after SG, are less severe after SG than after RYGB. For many other measures of 490 bone mass, microarchitecture, and estimated strength, our data do not provide evidence for differences between the surgical procedures, or our data even suggest larger changes after SG. 491 492 Postmenopausal women may be at highest risk of skeletal consequences after SG and RYGB, 493 and thus targeted screening, monitoring, and interventions may be particularly appropriate for postmenopausal women undergoing SG. Further research should evaluate approaches to the 494 495 prevention of long-term skeletal consequences of these otherwise beneficial metabolic procedures. 496 497 498

499 Acknowledgements

500 The authors thank Elliazar Enriquez, LVN for his facilitation of study recruitment; Aldric Chau for

501 his work on QCT scan analysis; and Dolores Shoback, MD for her expert advice.

503 References

Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity
 Among Adults: United States, 2017-2018. NCHS Data Brief. 2020(360):1-8.
 Global BMIMC, Di Angelantonio E, Bhupathiraju Sh N, Wormser D, Gao P, Kaptoge S,

et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239
 prospective studies in four continents. Lancet. 2016;388(10046):776-86.

Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity.
 Ann Transl Med. 2017;5(7):161.

- Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric
 surgery: a systematic review and meta-analysis. JAMA : the journal of the American Medical
 Association. 2004;292(14):1724-37.
- 5. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA surgery. 2014;149(3):275-87.

517 6. Nakamura KM, Haglind EG, Clowes JA, Achenbach SJ, Atkinson EJ, Melton LJ, 3rd, et 518 al. Fracture risk following bariatric surgery: a population-based study. Osteoporosis international 519 : a journal established as result of cooperation between the European Foundation for

520 Osteoporosis and the National Osteoporosis Foundation of the USA. 2014;25(1):151-8.

- 521 7. Stein EM, Silverberg SJ. Bone loss after bariatric surgery: causes, consequences, and 522 management. The lancet Diabetes & endocrinology. 2014;2(2):165-74.
- Rousseau C, Jean S, Gamache P, Lebel S, Mac-Way F, Biertho L, et al. Change in fracture risk and fracture pattern after bariatric surgery: nested case-control study. BMJ.
 2016;354:i3794.

Yu EW, Lee MP, Landon JE, Lindeman KG, Kim SC. Fracture Risk After Bariatric
 Surgery: Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding. J Bone Miner Res.
 2017;32(6):1229-36.

Axelsson KF, Werling M, Eliasson B, Szabo E, Näslund I, Wedel H, et al. Fracture Risk
After Gastric Bypass Surgery: A Retrospective Cohort Study. Journal of bone and mineral
research : the official journal of the American Society for Bone and Mineral Research.
2018;33(12):2122-31.

533 11. Gagnon C, Schafer AL. Bone Health After Bariatric Surgery. JBMR plus. 2018;2(3):121534 33.

535 12. Lindeman KG, Greenblatt LB, Rourke C, Bouxsein ML, Finkelstein JS, Yu EW.

Longitudinal 5-Year Evaluation of Bone Density and Microarchitecture After Roux-en-Y Gastric
 Bypass Surgery. The Journal of clinical endocrinology and metabolism. 2018;103(11):4104-12.

Schafer AL, Kazakia GJ, Vittinghoff E, Stewart L, Rogers SJ, Kim TY, et al. Effects of
 Gastric Bypass Surgery on Bone Mass and Microarchitecture Occur Early and Particularly

Impact Postmenopausal Women. Journal of bone and mineral research : the official journal of
 the American Society for Bone and Mineral Research. 2018;33(6):975-86.

542 14. Zhang Q, Chen Y, Li J, Chen D, Cheng Z, Xu S, et al. A meta-analysis of the effects of
543 bariatric surgery on fracture risk. Obes Rev. 2018;19(5):728-36.

544 15. Paccou J, Martignene N, Lespessailles E, Babykina E, Pattou F, Cortet B, et al. Gastric
545 Bypass But Not Sleeve Gastrectomy Increases Risk of Major Osteoporotic Fracture: French
546 Population-Based Cohort Study. J Bone Miner Res. 2020;35(8):1415-23.

547 16. Ponce J, Nguyen NT, Hutter M, Sudan R, Morton JM. American Society for Metabolic
548 and Bariatric Surgery estimation of bariatric surgery procedures in the United States, 2011549 2014. Surg Obes Relat Dis. 2015;11(6):1199-200.

550 17. Welbourn R, Hollyman M, Kinsman R, Dixon J, Liem R, Ottosson J, et al. Bariatric 551 Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the 552 Fourth IFSO Global Registry Report 2018. Obes Surg. 2019;29(3):782-95.

18. Howard R, Chao GF, Yang J, Thumma J, Chhabra K, Arterburn DE, et al. Comparative
Safety of Sleeve Gastrectomy and Gastric Bypass Up to 5 Years After Surgery in Patients With
Severe Obesity. JAMA Surg. 2021.

Biter LÚ, t Hart JW, Noordman BJ, Smulders JF, Nienhuijs S, Dunkelgrun M, et al. Longterm effect of sleeve gastrectomy vs Roux-en-Y gastric bypass in people living with severe
obesity: a phase III multicentre randomised controlled trial (SleeveBypass). Lancet Reg Health
Eur. 2024;38:100836.

MacNeil JA, Boyd SK. Accuracy of high-resolution peripheral quantitative computed
 tomography for measurement of bone quality. Med Eng Phys. 2007;29(10):1096-105.

562 21. Burghardt AJ, Kazakia GJ, Majumdar S. A local adaptive threshold strategy for high
 563 resolution peripheral quantitative computed tomography of trabecular bone. Ann Biomed Eng.
 564 2007;35(10):1678-86.

565 22. Carrasco F, Basfi-Fer K, Rojas P, Valencia A, Csendes A, Codoceo J, et al. Changes in 566 bone mineral density after sleeve gastrectomy or gastric bypass: relationships with variations in 567 vitamin D, ghrelin, and adiponectin levels. Obes Surg. 2014;24(6):877-84.

23. Carrasco F, Basfi-Fer K, Rojas P, Csendes A, Papapietro K, Codoceo J, et al. Calcium
absorption may be affected after either sleeve gastrectomy or Roux-en-Y gastric bypass in
premenopausal women: a 2-y prospective study. Am J Clin Nutr. 2018;108(1):24-32.

571 24. Muschitz C, Kocijan Ř, Marterer C, Nia ÁR, Muschitz GK, Resch H, et al. Sclerostin 572 levels and changes in bone metabolism after bariatric surgery. J Clin Endocrinol Metab. 573 2015;100(3):891-901.

574 25. Hsin MC, Huang CK, Tai CM, Yeh LR, Kuo HC, Garg A. A case-matched study of the 575 differences in bone mineral density 1 year after 3 different bariatric procedures. Surg Obes 576 Relat Dis. 2015;11(1):181-5.

Wu KC, Cao S, Weaver CM, King NJ, Patel S, Kim TY, et al. Intestinal Calcium
Absorption Decreases After Laparoscopic Sleeve Gastrectomy Despite Optimization of Vitamin
D Status. J Clin Endocrinol Metab. 2023;108(2):351-60.

580 27. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development 581 Conference Panel. Annals of internal medicine. 1991;115(12):956-61.

Schafer AL, Weaver CM, Black DM, Wheeler AL, Chang H, Szefc GV, et al. Intestinal
Calcium Absorption Decreases Dramatically After Gastric Bypass Surgery Despite Optimization
of Vitamin D Status. Journal of bone and mineral research : the official journal of the American
Society for Bone and Mineral Research. 2015;30(8):1377-85.

Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, et al.
Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support
of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical
Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery.
Endocrine practice : official journal of the American College of Endocrinology and the American

Association of Clinical Endocrinologists. 2013;19(2):337-72.

30. Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for
Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight
Loss Patient 2016 Update: Micronutrients. Surgery for obesity and related diseases : official
journal of the American Society for Bariatric Surgery. 2017;13(5):727-41.

31. Hacker-Thompson A, Robertson TP, Sellmeyer DE. Validation of two food frequency
questionnaires for dietary calcium assessment. Journal of the American Dietetic Association.
2009;109(7):1237-40.

599 32. Scherzer R, Shen W, Bacchetti P, Kotler D, Lewis CE, Shlipak MG, et al. Comparison of 600 dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue 601 depots in HIV-infected and control subjects. Am J Clin Nutr. 2008;88(4):1088-96.

33. Lang TF, Li J, Harris ST, Genant HK. Assessment of vertebral bone mineral density
 using volumetric quantitative CT. J Comput Assist Tomogr. 1999;23(1):130-7.

604 34. Khoo BC, Brown K, Cann C, Zhu K, Henzell S, Low V, et al. Comparison of QCT-derived 605 and DXA-derived areal bone mineral density and T scores. Osteoporos Int. 2009;20(9):1539-45.

Boutroy S, Van Rietbergen B, Sornay-Rendu E, Munoz F, Bouxsein ML, Delmas PD.
 Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with
 wrist fracture in postmenopausal women. J Bone Miner Res. 2008;23(3):392-9.

Melton LJ, 3rd, Riggs BL, van Lenthe GH, Achenbach SJ, Muller R, Bouxsein ML, et al.
Contribution of in vivo structural measurements and load/strength ratios to the determination of
forearm fracture risk in postmenopausal women. J Bone Miner Res. 2007;22(9):1442-8.

37. Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD. Alterations of cortical and trabecular
 architecture are associated with fractures in postmenopausal women, partially independent of

decreased BMD measured by DXA: the OFELY study. J Bone Miner Res. 2007;22(3):425-33.
Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone
microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin
Endocrinol Metab. 2005;90(12):6508-15.

618 39. Khosla S, Riggs BL, Atkinson EJ, Oberg AL, McDaniel LJ, Holets M, et al. Effects of sex 619 and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo 620 assessment. J Bone Miner Res. 2006;21(1):124-31.

40. Laib A, Hauselmann HJ, Ruegsegger P. In vivo high resolution 3D-QCT of the human forearm. Technol Health Care. 1998;6(5-6):329-37.

41. Kazakia GJ, Tjong W, Nirody JA, Burghardt AJ, Carballido-Gamio J, Patsch JM, et al.
The influence of disuse on bone microstructure and mechanics assessed by HR-pQCT. Bone.
2014;63:132-40.

42. Macneil JA, Boyd SK. Bone strength at the distal radius can be estimated from highresolution peripheral quantitative computed tomography and the finite element method. Bone.
2008;42(6):1203-13.

Mueller TL, Christen D, Sandercott S, Boyd SK, van Rietbergen B, Eckstein F, et al.
Computational finite element bone mechanics accurately predicts mechanical competence in
the human radius of an elderly population. Bone. 2011;48(6):1232-8.

44. Team RC. R: A language environment for statistical computing. 2021 [Available from:
https://www.R-project.org/.

Greendale GA, Sowers M, Han W, Huang MH, Finkelstein JS, Crandall CJ, et al. Bone
mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from
the Study of Women's Health Across the Nation (SWAN). J Bone Miner Res. 2012;27(1):111-8.
Okano I, Salzmann SN, Jones C, Ortiz Miller C, Shirahata T, Rentenberger C, et al. The

637 46. Okano I, Salzmann SN, Jones C, Ortiz Miller C, Shiranata T, Rentenberger C, et al. The
 638 impact of degenerative disc disease on regional volumetric bone mineral density (vBMD)
 639 measured by quantitative computed tomography. Spine J. 2020;20(2):181-90.

47. Van Gompel G, Van Slambrouck K, Defrise M, Batenburg KJ, de Mey J, Sijbers J, et al.
Iterative correction of beam hardening artifacts in CT. Med Phys. 2011;38 Suppl 1:S36.

48. Yu EW, Thomas BJ, Brown JK, Finkelstein JS. Simulated increases in body fat and

643 errors in bone mineral density measurements by DXA and QCT. J Bone Miner Res.644 2012;27(1):119-24.

Muschitz C, Kocijan R, Haschka J, Zendeli A, Pirker T, Geiger C, et al. The Impact of
Vitamin D, Calcium, Protein Supplementation, and Physical Exercise on Bone Metabolism After
Bariatric Surgery: The BABS Study. J Bone Miner Res. 2016;31(3):672-82.

50. Salman MA, Aradaib M, Salman A, Elewa A, Tourky M, Shaaban HE. Effects of Gastric
Bypass and Sleeve Gastrectomy on Bone Mineral Density and Bone Turnover Markers: A
Systematic Review and Meta-Analysis. World J Surg. 2022;46(4):865-75.

51 51. Bredella MA, Greenblatt LB, Eajazi A, Torriani M, Yu EW. Effects of Roux-en-Y gastric

bypass and sleeve gastrectomy on bone mineral density and marrow adipose tissue. Bone.

653 2017;95:85-90.

Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, et al. Clinical
practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients
undergoing bariatric procedures - 2019 update: cosponsored by American Association of
Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American
Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society
of Anesthesiologists. Surgery for obesity and related diseases : official journal of the American
Society for Bariatric Surgery. 2020;16(2):175-247.

	All (n = 54)	Premenopausal	Postmenopausal	Men
		women	women	(n = 13)
		(n = 26)	(n = 15)	
Age, yr	46.2 ± 11.1	38.5 ± 7.3	57.9 ± 6.4^{a}	$47.9 \pm 9.2^{a,b}$
Race, n (%)				
White	40 (74)	17 (65)	11 (73)	12 (92)
Black	10 (19)	6 (23)	4 (27)	
Asian	2 (4)	1 (4)		1 (8)
More than one race	2 (4)	2 (8)		
Ethnicity, n (%)				
Hispanic/Latinx	13 (24)	7 (27)	1 (7)	5 (38)
Weight, kg	126.0 ± 23.4	124.4 ± 20.3	111.9 ± 18.3	145.5 ± 22.6 ^{a,b}
BMI, kg/m²	45.2 ± 7.5	46.8 ± 7.6	42.0 ± 6.0	45.8 ± 8.2
Percent body fat (%)	43.8 ± 4.8	45.3 ± 4.0	45.1 ± 2.2	$38.5 \pm 5.7^{a,b}$
Waist circumference (cm)	119.7 ± 13.9	118.1 ± 11.1	114.2 ± 10.2	132.8 ± 18.3 ^{a,b}
Waist-hip ratio	0.86 ± 0.10	0.83 ± 0.07	0.85 ± 0.10	0.96 ± 0.10 ^{a,b}
Diabetes, n (%)	10 (19)	2 (8)	5 (33)	3 (23)
FCA, %	31.6 ± 15.0	35.6 ± 12.7	29.8 ± 17.7	22.0 ± 14.4
Serum calcium, mg/dL	9.3 ± 0.4	9.1 ± 0.3	9.4 ± 0.4^{a}	9.6 ± 0.4^{a}
Albumin, g/dL	4.1 ± 0.3	4.1 ± 0.2	4.1 ± 0.4	$4.4 \pm 0.4^{a,b}$
250HD preop visit, ng/mL	40.6 ± 13.7	38.0 ± 12.3	46.9 ± 12.7	37.8 ± 15.6
PTH, pg/mL	44.5 ± 22.5	38.9 ± 17.4	49.8 ± 28.1	49.0 ± 23.1
1,25(OH)₂D, pg/mL	70.0 ± 28.7	66.3 ± 28.5	73.9 ± 25.0	72.4 ± 34.5
CTx, ng/mL	0.20 (0.13,0.29)	0.15 (0.12,0.21)	0.26 (0.13,0.32)	0.31 (0.19,0.43) ^a
P1NP, ng/mL	42.4 (34.7,63.2)	36.8 (33.2,44.6)	52.3 (33.6,63.9)	64.2 (52.9,73.9) ^a
Creatinine, mg/dL	0.86 ± 0.31	0.70 ± 0.13	0.91 ± 0.37 ^a	1.10 ± 0.32 ^{a,b}
Phosphorus, mg/dL	3.6 ± 0.5	3.6 ± 0.5	3.6 ± 0.5	3.6 ± 0.5
Urinary calcium, mg/24hr	172 (80,270)	162 (91,240)	205 (57,375)	161 (95,269)
Areal BMD, g/cm ²	4 004 0 404	4 400 0 400	4 007 0 450	4 050 0 400
Lumbar spine	1.091 ± 0.131	1.108 ± 0.120	1.087 ± 0.153	1.056 ± 0.126
l otal hip	1.074 ± 0.123	1.099 ± 0.126	1.016 ± 0.125	1.104 ± 0.090
	0.901 ± 0.126	0.926 ± 0.133	0.846 ± 0.119	0.927 ± 0.103
volumetric BMD, g/cm ³	0.457 0.000	0.477 0.000	a 400 a ac=2	
Lumbar spine	0.157 ± 0.036	0.177 ± 0.029	0.139 ± 0.027^{a}	0.133 ± 0.034^{a}

Table 1. Baseline characteristics of SG participants

^ap<0.05 vs. premenopausal women

^bp<0.05 vs. postmenopausal women

Values are means ± SDs, median (IQR), or count (percentage).

95% reference intervals provided by the test manufacturers: PTH, 14-64 pg/mL; CTx, 0.034-1.037 ng/mL (post-menopausal women); P1NP, 27.7-127.6 ng/mL; 1,25(OH)₂D, 15.2-90.1 pg/mL.

Abbreviations: BMI, body mass index; FCA, fractional calcium absorption; 25OHD, 25-hydroxyvitamin D; PTH, intact parathyroid hormone; 1,25(OH)₂D, 1,25-dihydroxyvitamin D; CTx, collagen type 1 C-telopeptide; P1NP, procollagen 1 intact N-terminal propeptide; BMD, bone mineral density.

	6-month % change	12-month % change	р
<i>DXA</i> (n = 49)			
Total hip aBMD (g/cm ²)	-5.4 [-6.4,-4.3]	-8.0[-9.1,-6.7]	<0.01
Femoral neck aBMD (g/cm ²)	-3.4 [-4.2,-2.5]	-6.7 [-8.3,-5.2]	<0.01
Lumbar spine aBMD (g/cm ²)	-0.7 [-1.4,-0.1]	-1.4 [-2.6,-0.3]	0.03
Distal 1/3 radius aBMD (g/cm ²)	+0.3 [-0.1,0.7]	+0.7 [-0.1,1.6]	0.11
<i>QCT</i> (n = 38)			
Lumbar spine vBMD (g/cm ³)	-1.6 [-2.9,-0.1]	-3.1 [-6.1,0.1]	0.07
<i>HRpQCT</i> (n = 37)			
Radius total vBMD (g/cm ³)	-0.4 [-1.1,0.2]	-0.8 [-2.2,0.4]	0.22
Radius trabecular vBMD (g/cm ³)	-0.9[-1.6,-0.2]	-1.9[-3.3,-0.5]	0.01
Radius cortical vBMD (g/cm ³)	+0.2 [-0.1,0.4]	0.4 [-0.1,0.9]	0.17
Tibia total vBMD (g/cm ³)	-1.6 [-2.2,-1.0]	-3.1 [-4.2,-1.9]	<0.01
Tibia trabecular vBMD (g/cm ³)	-1.1 [-1.7,-0.4]	-2.1 [-3.3,-0.8]	<0.01
Tibia cortical vBMD (g/cm ³)	+0.0 [-0.6,0.7]	-1.0 [-2.2,0.1]	0.20

Table 2. Predicted percentage changes in BMD after SG

Values are model predictions ± 95%CI

P-values, which compare to no change, were calculated with mixed effect models with repeated measures with random participant intercept and slope and fixed effect of time.

Abbreviations: DXA, dual-energy X-ray absorptiometry; aBMD, areal bone mineral density; QCT, quantitative computed tomography; vBMD, volumetric bone mineral density; HRpQCT, high-resolution peripheral quantitative computed tomography.

HRpqCT (n = 37)	6-month % change	12-month % change	р
Bone microarchitecture			
Radius			
Trabecular area (mm²)	-0.1 [-0.3,0.2]	-0.1 [-0.6,0.3]	0.64
Trabecular number (per mm)	-2.8 [-4.0,-1.6]	-5.6[-8.0,-3.3]	<0.01
Trabecular separation (mm)	+3.3 [1.1,5.4]	+6.6 [2.6,11.0]	<0.01
Trabecular thickness (mm)	+1.7 [0.1,3.4]	+3.3 [0.1,6.3]	0.04
Trabecular heterogeneity (per mm)	+7.6 [0.7,14.4]	+15.2 [0.5,29.4]	0.05
Cortical thickness (mm)	-0.1 [-0.7,0.6]	-0.2[-1.5,1.1]	0.77
Cortical porosity (%)	-0.3 [-4.0,3.7]	-0.5 [-7.7,7.4]	0.90
Cortical pore size (mm)	+1.8 [0.7,2.9]	+3.5 [1.4,5.6]	<0.01
Tibia			
Trabecular area (mm²)	+0.3 [0.2,0.5]	+0.7 [0.4,1.0]	<0.01
Trabecular number (per mm)	-4.2 [-5.3,-2.9]	-8.3 [-10.7,-5.9]	<0.01
Trabecular separation (mm)	+5.0 [3.2,6.7]	+10.0 [6.2,13.6]	<0.01
Trabecular thickness (mm)	+3.1 [1.4,5.0]	+6.3 [2.6,9.8]	<0.01
Trabecular heterogeneity (per mm)	+6.6 [4.4,8.9]	+13.2 [8.4,17.3]	<0.01
Cortical thickness (mm)	-1.3[-2.1,-0.6]	-2.6[-4.2,-1.1]	<0.01
Cortical porosity (%)	+2.7 [-2.0,7.7]	+5.5 [-4.0,15.3]	0.24
Cortical pore size (mm)	+2.7 [1.7,3.7]	+5.4 [3.3,7.4]	<0.01
Estimated strength			
Radius			
Failure load (kN)	-0.5 [-1.2,0.3]	-0.9[-2.4,0.5]	0.20
Stiffness (kN/mm)	-0.1 [-1.1,0.8]	-0.3[-2.2,1.6]	0.77
Apparent modulus (kN/mm ²)	-0.3 [-1.2,0.5]	-0.7 [-2.2,1.1]	0.44
Tibia			
Failure load (kN)	-1.1 [-1.9,-0.3]	-2.3[-3.9,-0.7]	<0.01
Stiffness (kN/mm)	-0.8 [-1.7,0.1]	-1.7[-3.4,-0.1]	0.06
Apparent modulus (kN/mm ²)	-0.9[-1.7,-0.1]	-1.8[-3.5,-0.1]	0.04

 Table 3. Predicted percentage changes in bone microarchitecture and estimated strength after

 SG

Values are model prediction ± 95%Cl

P-values, which compare to no change, were calculated with mixed effect models with repeated measures with random participant intercept and slope and fixed effect of time

Abbreviations: DXA, dual-energy X-ray absorptiometry; aBMD, areal bone mineral density; QCT, quantitative computed tomography; vBMD, volumetric bone mineral density; HRpQCT, high-resolution peripheral quantitative computed tomography.



Figure 1: Changes in BMD, bone microarchitecture, and estimated strength that were significantly different by sex and menopausal status. Shaded areas represent the 95% confidence intervals.



Figure 2: Changes in BMD, bone microarchitecture, and estimated strength that were significantly different by surgical procedure. Shaded areas represent the 95% confidence intervals.